Healthcare Innovation

A new book by a top physician-scientist challenges the idea that innovation comes from the private sector, arguing Medicaid is a lab for bold experiments.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

The spinal device firm will meet investors at the key small-cap conference, balancing a story of innovation against mixed financial results.

Bel Group's massive $200M investment in its South Dakota Babybel plant will double production, add 150 jobs, and capitalize on America's new snacking habits.

Thorne released impressive consumer data for its supplements. But what do these studies really mean for consumers in a crowded, unregulated market?

Newly published research brings scientific rigor to the controversial kratom plant, influencing policy from the FDA to statehouses across the nation.

The biotech plans to separate its R&D pipeline from its booming royalty assets, creating two public companies and winning applause from Wall Street.

A 10-year, $25M program created 108 palliative care leaders. A new report reveals its impact on a field facing a critical workforce and access crisis.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

Neogen divests its pioneering genomics business for $160M to slash debt, while Zoetis bolsters its dominance in the animal health diagnostics market.

Argo Biopharma's new CFO/CSO, Dr. Gena Wang, leaves a star analyst career at Barclays, signaling a major validation for the company's siRNA platform.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

A new FDA-cleared device promises to make the removal of ruptured breast implants faster, cleaner, and safer, addressing a major concern for patients and surgeons.

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With stellar trial data and a fast-tracked FDA submission, CG Oncology prepares for a pivotal presentation at the TD Cowen Health Care Conference.